All lobbying filings

VIATRIS INC.

Lobbying for VIATRIS INC

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Pennsylvania · House · Senate · $360,000.00 expenses · posted Jul 20, 2026

Official filing document

Bills named in this filing 7

S 891
Bipartisan Health Care Act
HR 4132
Prescription Information Modernization Act of 2025
S 2027
Prescription Information Modernization Act of 2025
S 2658
Medication Affordability and Patent Integrity Act
S 3778
Carbon Resource Innovation Act
S 3841
Last Sale Valuation Act of 2026
S 2296
National Defense Authorization Act for Fiscal Year 2026

Lobbying activity 5

Health Issues

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act

IP Issues related to generic medicines Patent Settlements

Trade (domestic/foreign)

Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act

Financial Institutions/Investments/Securities

Policy related to corporate governance

Defense

S.2296 National Defense Authorization Act

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.